---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-14T17:11:48.958127'
end_time: '2025-12-14T17:17:29.472565'
duration_seconds: 340.52
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: CYB5D2
  gene_symbol: CYB5D2
  uniprot_accession: Q8WUJ1
  protein_description: 'RecName: Full=Neuferricin; AltName: Full=Cytochrome b5 domain-containing
    protein 2; Flags: Precursor;'
  gene_info: Name=CYB5D2 {ECO:0000312|HGNC:HGNC:28471};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the cytochrome b5 family. MAPR subfamily.
  protein_domains: Cyt_B5-like_heme/steroid-bd. (IPR001199); Cyt_B5-like_heme/steroid_sf.
    (IPR036400); MAPR/NEUFC/NENF-like. (IPR050577); Cyt-b5 (PF00173)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 8
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8WUJ1
- **Protein Description:** RecName: Full=Neuferricin; AltName: Full=Cytochrome b5 domain-containing protein 2; Flags: Precursor;
- **Gene Information:** Name=CYB5D2 {ECO:0000312|HGNC:HGNC:28471};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the cytochrome b5 family. MAPR subfamily.
- **Key Domains:** Cyt_B5-like_heme/steroid-bd. (IPR001199); Cyt_B5-like_heme/steroid_sf. (IPR036400); MAPR/NEUFC/NENF-like. (IPR050577); Cyt-b5 (PF00173)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CYB5D2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CYB5D2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CYB5D2** (gene ID: CYB5D2, UniProt: Q8WUJ1) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8WUJ1
- **Protein Description:** RecName: Full=Neuferricin; AltName: Full=Cytochrome b5 domain-containing protein 2; Flags: Precursor;
- **Gene Information:** Name=CYB5D2 {ECO:0000312|HGNC:HGNC:28471};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the cytochrome b5 family. MAPR subfamily.
- **Key Domains:** Cyt_B5-like_heme/steroid-bd. (IPR001199); Cyt_B5-like_heme/steroid_sf. (IPR036400); MAPR/NEUFC/NENF-like. (IPR050577); Cyt-b5 (PF00173)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "CYB5D2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'CYB5D2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **CYB5D2** (gene ID: CYB5D2, UniProt: Q8WUJ1) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan
Objective 1: Verify CYB5D2 identity (UniProt Q8WUJ1), organism, and domain/family membership. Completed by cross-referencing primary and review literature that explicitly describe human CYB5D2/Neuferricin as a MAPR-family, cytochrome b5–like protein with an N‑terminal membrane region and a cyt-b5–like heme-binding domain (including a critical D86 residue). (bruce2014cyb5d2requireshemebinding pages 1-2, ryu2017membraneassociatedprogesterone pages 2-3)
Objective 2: Collect recent and foundational literature. Completed using a mechanistic primary paper (2014), a cancer-association study (2019), and MAPR reviews. Few CYB5D2-specific papers in 2023–2024 were located; we note this limitation. (bruce2014cyb5d2requireshemebinding pages 1-2, bruce2014cyb5d2requireshemebinding pages 11-12, bruce2014cyb5d2requireshemebinding pages 12-13, ojo2019downregulationofcyb5d2 pages 11-11, ryu2017membraneassociatedprogesterone pages 2-3, ryu2017membraneassociatedprogesterone pages 3-4, ojo2019downregulationofcyb5d2 pages 5-7)
Objective 3: Extract evidence on function, localization, interactions, and pathways. Completed from Bruce & Rybak (2014) and summarized in table. (bruce2014cyb5d2requireshemebinding pages 1-2, bruce2014cyb5d2requireshemebinding pages 11-12, bruce2014cyb5d2requireshemebinding pages 12-13)
Objective 4: Summarize applications/associations and statistics. Completed using Ojo et al. (2019) and Bruce & Rybak (2014) quantitative data. (ojo2019downregulationofcyb5d2 pages 11-11, ojo2019downregulationofcyb5d2 pages 5-7, bruce2014cyb5d2requireshemebinding pages 12-13)
Objective 5: Create an evidence summary artifact. Completed (artifact-00).
Objective 6: Write and submit comprehensive report with citations, URLs, and dates. Completed below.

Comprehensive Research Report: CYB5D2 (Neuferricin; UniProt Q8WUJ1)

1) Key concepts and definitions
• Identity and family: CYB5D2 (gene symbol CYB5D2; protein “Neuferricin”) is a human member of the membrane-associated progesterone receptor (MAPR) family and belongs to the broader cytochrome b5-like superfamily. It contains a conserved cytochrome b5-like heme/steroid-binding domain. These features match the UniProt description for Q8WUJ1 and confirm Homo sapiens as the organism. Bruce and Rybak characterized human CYB5D2 as a MAPR-family protein with a cyt-b5–like domain; Ryu et al. reviewed MAPR family architecture and place CYB5D2 among the four MAPRs (PGRMC1, PGRMC2, NENF, CYB5D2). URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01); https://doi.org/10.3389/fphar.2017.00159 (2017-03-23) (bruce2014cyb5d2requireshemebinding pages 1-2, ryu2017membraneassociatedprogesterone pages 2-3)
• Domain architecture: CYB5D2 has an N-terminal transmembrane/signal segment and a C-terminal cytochrome b5-like domain. Heme-binding involves conserved residues analogous to MAPRs; mutation of Asp86 (D86G) abolishes heme binding, establishing D86 as critical. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01) (bruce2014cyb5d2requireshemebinding pages 1-2, bruce2014cyb5d2requireshemebinding pages 11-12)

2) Molecular function, substrate specificity, and mechanism
• Molecular role: CYB5D2 is not a classical enzyme with a defined catalytic reaction; rather, it functions as a heme-dependent regulatory/adaptor protein that modulates cytochrome P450 (CYP)-related processes and cellular survival pathways. Heme binding is required for its biological effects. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01); https://doi.org/10.3389/fphar.2017.00159 (2017-03-23) (bruce2014cyb5d2requireshemebinding pages 1-2, ryu2017membraneassociatedprogesterone pages 2-3)
• Heme-binding residues: Conservation analyses and mutagenesis indicate roles for Y73, Y79, and Y127, with definitive evidence that D86 is essential for heme binding (D86G mutant loses heme binding). URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01) (bruce2014cyb5d2requireshemebinding pages 1-2)
• CYP system modulation: CYB5D2 co-localizes with NADPH–cytochrome P450 oxidoreductase (POR/CYPOR) and influences CYP protein levels and activity. Knockdown reduces the sterol biosynthesis enzyme CYP51A1 (lanosterol 14α-demethylase) levels and decreases CYP3A4 activity, linking CYB5D2 to sterol synthesis and drug metabolism. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01) (bruce2014cyb5d2requireshemebinding pages 1-2)

3) Cellular/subcellular localization and secretion
• Localization: CYB5D2 localizes predominantly to the endoplasmic reticulum/perinuclear region. Both WT and D86G heme-binding–defective proteins localize to ER, indicating localization does not require heme binding. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01) (bruce2014cyb5d2requireshemebinding pages 1-2)
• Secretion: Secreted forms have been observed in heterologous expression systems, and secretion requires intact heme-binding capacity (loss with D86G). Thus, secretion is context-dependent and heme-dependent. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01); review summary: https://doi.org/10.3389/fphar.2017.00159 (2017-03-23) (bruce2014cyb5d2requireshemebinding pages 11-12, ryu2017membraneassociatedprogesterone pages 2-3)

4) Interaction partners and pathway context
• Interaction proximity: Co-localization with POR places CYB5D2 in proximity to ER-resident CYP monooxygenase complexes, consistent with MAPR-family roles in CYP regulation. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01) (bruce2014cyb5d2requireshemebinding pages 1-2)
• Pathways: Functional evidence ties CYB5D2 to the mevalonate/sterol biosynthesis pathway via CYP51A1 modulation and to xenobiotic metabolism via effects on CYP3A4 activity. Knockdown sensitizes cells to mevalonate perturbation, indicating functional engagement with sterol biosynthesis. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01) (bruce2014cyb5d2requireshemebinding pages 1-2)

5) Cellular phenotypes and disease associations
• Cell biology phenotypes: In HeLa cells, CYB5D2 overexpression inhibits proliferation and anchorage-independent growth; knockdown or expression of the D86G heme-binding–defective mutant increases proliferation. CYB5D2 expression enhances survival after chemotherapeutics (paclitaxel, cisplatin, doxorubicin), and this survival effect requires heme binding. Mechanistically, ectopic expression can modulate levels of cell-cycle regulators and AKT activation in response to genotoxic stress. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01) (bruce2014cyb5d2requireshemebinding pages 1-2, bruce2014cyb5d2requireshemebinding pages 12-13)
• Cancer associations: Multi-cohort analyses in breast cancer show CYB5D2 downregulation associates with progression and worse outcomes. A CYB5D2-derived 21‑gene signature predicted shorter overall survival and independently associated with breast cancer mortality (e.g., HR ≈ 1.28; 95% CI 1.08–1.52; p ≈ 0.004). CYB5D2 reductions co-occur statistically with TP53 and RB1 alterations and show relationships with PIK3CA, GATA3, MAP3K1, and CDH1 status. URL: https://doi.org/10.1038/s41598-019-43006-y (2019-04-25) (ojo2019downregulationofcyb5d2 pages 11-11, ojo2019downregulationofcyb5d2 pages 5-7)

6) Recent developments (2023–2024) and expert analyses
• CYB5D2-specific literature in 2023–2024 appears sparse. Contemporary discussions of the MAPR family continue to emphasize roles as heme-dependent regulators of CYP systems and steroid/cholesterol metabolism; however, detailed new mechanistic or clinical CYB5D2-specific advances were not identified in our 2023–2024 scan. This highlights a knowledge gap relative to PGRMC1/NENF within MAPRs. URL: MAPR review context: https://doi.org/10.3389/fphar.2017.00159 (2017-03-23) (ryu2017membraneassociatedprogesterone pages 2-3)

7) Current applications and real-world implementations
• Research tools and implications: CYB5D2 can be used experimentally to modulate CYP-linked pathways in cell systems—knockdown and overexpression alter CYP51A1 levels and CYP3A4 activity, with measurable effects on sterol pathway sensitivity and drug response phenotypes. These findings suggest potential utility as a biomarker of CYP pathway integrity or therapeutic response in preclinical models, and support exploration of CYB5D2 status in cancer datasets. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01); https://doi.org/10.1038/s41598-019-43006-y (2019-04-25) (bruce2014cyb5d2requireshemebinding pages 1-2, ojo2019downregulationofcyb5d2 pages 11-11)

8) Expert opinions and analysis
• MAPR context: Reviews emphasize that MAPR proteins, including CYB5D2, are small heme-binding adaptors related to cytochrome b5 and often influence CYP enzymes and steroid/cholesterol pathways, with pleiotropic cellular effects. CYB5D2 is less characterized than PGRMC1, and conclusions are drawn cautiously due to model limitations and reliance on cell-based assays. URL: https://doi.org/10.3389/fphar.2017.00159 (2017-03-23) (ryu2017membraneassociatedprogesterone pages 2-3, ryu2017membraneassociatedprogesterone pages 3-4)

9) Relevant statistics and quantitative data
• Heme-binding dependence: D86G mutation abolishes heme binding; both WT and D86G localize to ER, but only heme-binding–competent CYB5D2 supports secretion and chemotherapeutic survival phenotypes. Significance thresholds for cellular assays were reported (e.g., p<0.05, p<0.01) across multiple drug survival curves. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01) (bruce2014cyb5d2requireshemebinding pages 11-12, bruce2014cyb5d2requireshemebinding pages 12-13)
• CYP modulation: CYB5D2 knockdown reduced CYP51A1 protein levels and decreased CYP3A4 activity; knockdown increased sensitivity to mevalonate. Quantitative assay specifics, including normalized luciferase-based readouts for CYP3A4 activity, are provided in the primary study. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01) (bruce2014cyb5d2requireshemebinding pages 1-2)
• Clinical statistics: In breast cancer cohorts, a CYB5D2-derived 21‑gene signature correlated with overall survival and independently predicted mortality (e.g., HR ≈ 1.28, 95% CI 1.08–1.52, p ≈ 0.004), with strong enrichment of TP53 mutations among signature-positive tumors (≈85%). URL: https://doi.org/10.1038/s41598-019-43006-y (2019-04-25) (ojo2019downregulationofcyb5d2 pages 11-11, ojo2019downregulationofcyb5d2 pages 5-7)

Verification of identity and avoidance of symbol ambiguity
• CYB5D2 here refers strictly to Homo sapiens Neuferricin (UniProt Q8WUJ1), a MAPR-family cytochrome b5-like protein. We did not use literature pertaining to similarly named genes in non-human organisms or unrelated symbols. The protein family/domains and functional features described in the literature match the UniProt context provided. URL: https://doi.org/10.1371/journal.pone.0086435 (2014-01); https://doi.org/10.3389/fphar.2017.00159 (2017-03-23) (bruce2014cyb5d2requireshemebinding pages 1-2, ryu2017membraneassociatedprogesterone pages 2-3)

Quick-reference evidence summary
| Aspect | Evidence / Details | Key Data / Statistics | Source (year and URL) |
|---|---|---:|---|
| Identity & family | Human CYB5D2 (Neuferricin), MAPR subfamily of cytochrome b5-like proteins; UniProt Q8WUJ1 reported as cytochrome b5 domain-containing protein 2 (neuferricin). | Protein length ~264 aa; MAPR / cyt-b5-like family membership. | Bruce & Rybak 2014: https://doi.org/10.1371/journal.pone.0086435 (2014) (bruce2014cyb5d2requireshemebinding pages 1-2), Ryu et al. 2017: https://doi.org/10.3389/fphar.2017.00159 (2017) (ryu2017membraneassociatedprogesterone pages 2-3) |
| Domain architecture & critical residues | N-terminal transmembrane (TM) / signal segment + C-terminal cytochrome b5-like (heme/steroid-binding) domain; candidate heme-contact residues Y73, Y79, D86, Y127. | D86 substitution (D86G) abolishes heme binding (functional loss). | Bruce & Rybak 2014: https://doi.org/10.1371/journal.pone.0086435 (2014) (bruce2014cyb5d2requireshemebinding pages 1-2), Ryu et al. 2017 (ryu2017membraneassociatedprogesterone pages 2-3) |
| Molecular role (enzyme vs adaptor) | Functions as a heme-dependent regulatory/adaptor (MAPR) rather than a canonical enzyme; modulates activities of CYP enzymes and cell survival pathways. | Heme-binding is required for regulatory functions (e.g., chemoresistance); not described as catalyzing a biochemical reaction. | Bruce & Rybak 2014 (bruce2014cyb5d2requireshemebinding pages 1-2), Ryu et al. 2017 (ryu2017membraneassociatedprogesterone pages 2-3) |
| CYP-related effects | CYB5D2 co-localizes with cytochrome P450 reductase (POR/CYPOR) and influences CYP protein levels and activities. | CYB5D2 knockdown reduced lanosterol demethylase (CYP51A1) protein levels and decreased CYP3A4 activity; knockdown rendered cells mevalonate-sensitive. | Bruce & Rybak 2014: https://doi.org/10.1371/journal.pone.0086435 (2014) (bruce2014cyb5d2requireshemebinding pages 1-2) |
| Subcellular localization & secretion | Predominantly endoplasmic reticulum / perinuclear localization; secretion observed in some contexts but requires intact heme-binding. | TM + cyt-b5 domains required for perinuclear/ER localization; heme-binding competent protein can be secreted in 293T assays. | Bruce & Rybak 2014 (bruce2014cyb5d2requireshemebinding pages 1-2), Ryu et al. 2017 (ryu2017membraneassociatedprogesterone pages 2-3) |
| Interaction partners | Co-localizes with POR/CYPOR; MAPR-family functional parallels with PGRMC1/PGRMC2 and NENF but direct stable interactome remains limited. | Co-localization with CYPOR demonstrated in cell studies (supporting proximity to CYP systems). | Bruce & Rybak 2014 (bruce2014cyb5d2requireshemebinding pages 1-2), review evidence (ryu2017membraneassociatedprogesterone pages 2-3) |
| Cellular phenotypes (gain/loss) | Overexpression often inhibits proliferation/anchorage-independent growth; knockdown or heme-binding–defective mutant increases proliferation; CYB5D2 expression promotes survival to multiple chemotherapeutics. | In HeLa cells: CYB5D2 overexpression decreased proliferation/colony formation; CYB5D2(D86G) or knockdown increased proliferation; expression conferred resistance to paclitaxel, cisplatin, doxorubicin. | Bruce & Rybak 2014 (bruce2014cyb5d2requireshemebinding pages 1-2); supporting tumor-cell context studies cited in Ojo et al. 2019 (ojo2019downregulationofcyb5d2 pages 11-11) |
| Pathways / biochemical context | Implicated in sterol biosynthesis regulation and drug metabolism (via CYP modulation); influences mevalonate/lanosterol-related sensitivity. | Knockdown → reduced CYP51A1 (lanosterol demethylase) → increased sensitivity to mevalonate pathway perturbation; reduced CYP3A4 activity (drug metabolism impact). | Bruce & Rybak 2014 (bruce2014cyb5d2requireshemebinding pages 1-2) |
| Disease associations & clinical data | CYB5D2 downregulation associated with breast cancer progression; proposed tumor-suppressor role and prognostic gene signature; links to TP53/RB1 alterations reported. | CYB5D2-derived 21-gene signature correlated with shorter overall survival; signature independently predicted breast-cancer death (example: HR ~1.28, 95% CI 1.08–1.52, p~0.004 reported). | Ojo et al. 2019: https://doi.org/10.1038/s41598-019-43006-y (2019) (ojo2019downregulationofcyb5d2 pages 11-11, ojo2019downregulationofcyb5d2 pages 5-7) |
| Notes, recency & limitations | CYB5D2-specific experimental literature is limited vs other MAPRs (PGRMC1); most mechanistic cellular work dates to 2010s–2019; few CYB5D2-specific studies in 2023–2024. | Evidence base: key mechanistic study (Bruce 2014) and tumor association study (Ojo 2019); reviews summarize MAPR family but CYB5D2 remains less characterized. | Review & experimental sources: Bruce 2014 (bruce2014cyb5d2requireshemebinding pages 1-2), Ryu 2017 (ryu2017membraneassociatedprogesterone pages 2-3), Ojo 2019 (ojo2019downregulationofcyb5d2 pages 11-11) |


*Table: Concise evidence summary for human CYB5D2 (Neuferricin, UniProt Q8WUJ1) showing identity, domains, key functional findings, localization, CYP-related effects, cellular phenotypes, and disease associations with primary-source citations useful for quick reference.*

Limitations and open questions
• CYB5D2 biology remains comparatively underexplored relative to other MAPRs. Confirmatory biochemical interaction studies (e.g., direct physical interaction with POR/CYPs), in vivo models, and clinical validation studies are needed. Few CYB5D2-specific publications from 2023–2024 were identified in our search; conclusions rely primarily on the 2014 mechanistic study and a 2019 clinical association study. (bruce2014cyb5d2requireshemebinding pages 1-2, ojo2019downregulationofcyb5d2 pages 11-11)

References

1. (bruce2014cyb5d2requireshemebinding pages 1-2): Anthony Bruce and Adrian P. Rybak. Cyb5d2 requires heme-binding to regulate hela cell growth and confer survival from chemotherapeutic agents. PLoS ONE, 9:e86435, Jan 2014. URL: https://doi.org/10.1371/journal.pone.0086435, doi:10.1371/journal.pone.0086435. This article has 23 citations and is from a peer-reviewed journal.

2. (ryu2017membraneassociatedprogesterone pages 2-3): Chang S. Ryu, Kathrin Klein, and Ulrich M. Zanger. Membrane associated progesterone receptors: promiscuous proteins with pleiotropic functions – focus on interactions with cytochromes p450. Frontiers in Pharmacology, Mar 2017. URL: https://doi.org/10.3389/fphar.2017.00159, doi:10.3389/fphar.2017.00159. This article has 128 citations and is from a poor quality or predatory journal.

3. (bruce2014cyb5d2requireshemebinding pages 11-12): Anthony Bruce and Adrian P. Rybak. Cyb5d2 requires heme-binding to regulate hela cell growth and confer survival from chemotherapeutic agents. PLoS ONE, 9:e86435, Jan 2014. URL: https://doi.org/10.1371/journal.pone.0086435, doi:10.1371/journal.pone.0086435. This article has 23 citations and is from a peer-reviewed journal.

4. (bruce2014cyb5d2requireshemebinding pages 12-13): Anthony Bruce and Adrian P. Rybak. Cyb5d2 requires heme-binding to regulate hela cell growth and confer survival from chemotherapeutic agents. PLoS ONE, 9:e86435, Jan 2014. URL: https://doi.org/10.1371/journal.pone.0086435, doi:10.1371/journal.pone.0086435. This article has 23 citations and is from a peer-reviewed journal.

5. (ojo2019downregulationofcyb5d2 pages 11-11): Diane Ojo, David Rodriguez, Fengxiang Wei, Anita Bane, and Damu Tang. Downregulation of cyb5d2 is associated with breast cancer progression. Scientific Reports, Apr 2019. URL: https://doi.org/10.1038/s41598-019-43006-y, doi:10.1038/s41598-019-43006-y. This article has 15 citations and is from a peer-reviewed journal.

6. (ryu2017membraneassociatedprogesterone pages 3-4): Chang S. Ryu, Kathrin Klein, and Ulrich M. Zanger. Membrane associated progesterone receptors: promiscuous proteins with pleiotropic functions – focus on interactions with cytochromes p450. Frontiers in Pharmacology, Mar 2017. URL: https://doi.org/10.3389/fphar.2017.00159, doi:10.3389/fphar.2017.00159. This article has 128 citations and is from a poor quality or predatory journal.

7. (ojo2019downregulationofcyb5d2 pages 5-7): Diane Ojo, David Rodriguez, Fengxiang Wei, Anita Bane, and Damu Tang. Downregulation of cyb5d2 is associated with breast cancer progression. Scientific Reports, Apr 2019. URL: https://doi.org/10.1038/s41598-019-43006-y, doi:10.1038/s41598-019-43006-y. This article has 15 citations and is from a peer-reviewed journal.

## Citations

1. ryu2017membraneassociatedprogesterone pages 2-3
2. ryu2017membraneassociatedprogesterone pages 3-4
3. https://doi.org/10.1371/journal.pone.0086435
4. https://doi.org/10.3389/fphar.2017.00159
5. https://doi.org/10.1038/s41598-019-43006-y
6. https://doi.org/10.1371/journal.pone.0086435,
7. https://doi.org/10.3389/fphar.2017.00159,
8. https://doi.org/10.1038/s41598-019-43006-y,